About Immutrix Therapeutics
Immutrix Therapeutics is a company based in Rapid City (United States) founded in 2009 by Carol Rae.. Immutrix Therapeutics has raised $14.02 million across 6 funding rounds. Immutrix Therapeutics offers products and services including Blood-Cleansing Device and Extracorporeal System. Immutrix Therapeutics operates in a competitive market with competitors including Haemonetics, Vetex Medical, MediSieve, Hemostasis and Immunocept Medical Products, among others.
- Headquarter Rapid City, United States
- Founders Carol Rae
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Immutrix Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$14.02 M (USD)
in 6 rounds
-
Latest Funding Round
$480 K (USD), Debt – Conventional
Sep 18, 2025
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immutrix Therapeutics
Immutrix Therapeutics offers a comprehensive portfolio of products and services, including Blood-Cleansing Device and Extracorporeal System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Device removes harmful molecules from blood to treat medical conditions.
System modulates blood components for rapid-response disease treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Immutrix Therapeutics
Immutrix Therapeutics has successfully raised a total of $14.02M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $480 thousand completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Debt – Conventional — $480,000
-
First Round
First Round
(20 Oct 2015)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Debt – Conventional - Immutrix Therapeutics | Valuation |
investors |
|
| Jul, 2020 | Amount | Series A - Immutrix Therapeutics | Valuation |
investors |
|
| Sep, 2019 | Amount | Series A - Immutrix Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Immutrix Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immutrix Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immutrix Therapeutics Comparisons
Competitors of Immutrix Therapeutics
Immutrix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, MediSieve, Hemostasis and Immunocept Medical Products, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Hematology products and solutions are provided for medical applications.
|
|
| domain | founded_year | HQ Location |
Catheters for venous clot management and removal are developed.
|
|
| domain | founded_year | HQ Location |
Magnetic therapy is developed to treat blood-borne diseases.
|
|
| domain | founded_year | HQ Location |
Develops and manufactures hemostatic products for surgical bleeding control and patient care.
|
|
| domain | founded_year | HQ Location |
Blood filtration therapy for severe sepsis is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Immutrix Therapeutics
When was Immutrix Therapeutics founded?
Immutrix Therapeutics was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Where is Immutrix Therapeutics located?
Immutrix Therapeutics is headquartered in Rapid City, United States. It is registered at Rapid City, South Dakota, United States.
Who is the current CEO of Immutrix Therapeutics?
Carol Rae is the current CEO of Immutrix Therapeutics. They have also founded this company.
Is Immutrix Therapeutics a funded company?
Immutrix Therapeutics is a funded company, having raised a total of $14.02M across 6 funding rounds to date. The company's 1st funding round was a Series A of $450K, raised on Oct 20, 2015.
What does Immutrix Therapeutics do?
Immutrix Therapeutics develops blood cleansing treatment device. It removes inflammatory mediators and toxins from blood using proprietary adsorbents and smart hollow fiber membranes. It cleanses whole blood to modulate and sequester molecules from circulation. It targets and binds molecules to treat a broad range of medical conditions.
Who are the top competitors of Immutrix Therapeutics?
Immutrix Therapeutics's top competitors include Haemonetics, Vetex Medical and MediSieve.
What products or services does Immutrix Therapeutics offer?
Immutrix Therapeutics offers Blood-Cleansing Device and Extracorporeal System.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.